Stockreport

Lisata Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update

Lisata Therapeutics, Inc.  (LSTA) 
PDF Data rich period continues to support certepetide’s broad applicability and effectiveness Catalent enters into global license agreement for the use of certepetide as pa [Read more]